Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.
Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...
Clinical Trials Arena on MSN2d
Moleculin Biotech gains approval for enrolment in trial of AML therapy in UkraineUS-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III trial of annamycin with cytarabine for treating acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback